Protein-targeting vaccine extends survival in glioblastoma

February 8, 2019
A vaccine that targets the protein survivin appeared safe and extended survival among patients with newly diagnosed glioblastoma, according to…
Molecular Oncology

Personalized context of the cancer cell

HemOnc Today, February 10, 2019
Sofia D. Merajver, MD, PhD
For decades, prognostic markers and therapeutics have been focused largely on the cancer cell’s growth patterns in tissue culture or in animal…

Researchers tap genomic technology to develop personalized treatments for pediatric glioma

February 3, 2019
Researchers at UCSF Benioff Children’s Hospitals are using next-generation genomic technology to develop targeted therapies for high-grade…
Meeting News

DA-EPOCH shows promise in newly diagnosed acute lymphoblastic leukemia

January 24, 2019
SAN DIEGO — Researchers at the ASH Annual Meeting and Exposition reported that dose-adjusted etoposide, prednisone, vincristine…

Solutions needed to lower 'unsustainable cost' of care for hematologic malignancies

January 23, 2019
Treatment costs for hematologic malignancies exceed those of other cancer types, and they place lasting burdens on patients and the health care…

Association of American Cancer Institutes launches initiative to advance CAR T-cell therapies

January 22, 2019
Association of American Cancer Institutes launched a national initiative to advance the use of chimeric antigen receptor T-cell therapies. The…

Trial to assess CAR T-cell therapy for HER2-positive metastatic breast cancer

January 19, 2019
Researchers at City of Hope have opened a first-in-human clinical trial to assess the use of chimeric antigen receptor T-cell therapy for patients…

CIMAvax-nivolumab combination appears safe, demonstrates ‘good signals’ in advanced lung cancer

January 18, 2019
The Cuban-developed immunotherapy CIMAvax-EGF in combination with nivolumab appeared safe for patients with advanced non-small cell lung cancer…
Molecular Oncology

‘Cancer-agnostic’ NTRK inhibitor approval ushers in paradigm of personalized genomics-guided therapeutics

HemOnc Today, January 10, 2019
Patrick C. Ma, MD, MSc
On Nov. 26, the FDA announced the accelerated approval of larotrectinib as the first small molecule inhibitor for use in a…
Cover Story

Checkpoint inhibition and rheumatic events: ‘Many more questions than answers’

HemOnc Today, January 10, 2019
It may seem silly to use Whac-A-Mole to illustrate a key challenge in cancer treatment. But the popular arcade game’s basic premise — use…